Kayeong Shin, MD

So excited to see this work presented! Congrats @Kolade__Olabode 🎉

Thank you so much for the coffee, Dr. @jihyunRadOnc ! ❤️🥰 Thanks to you, I had my first Philz Coffee in San Francisco! Hope to see you again at ASTRO and @KoreanASTRO next year.

📢 JAMA Oncol (Oct 2, 2025): Phase 2 RCT: PSMA PET–guided intensification of salvage RT post-prostatectomy shows improved biochemical control vs standard RT. ➡️ Suggests molecular imaging can personalize salvage therapy. 👉10.1001/jamaoncol.2025.3625 @JAMAOnc @ONCOassist @OncoAlert #cancer #Oncology #MedX @APCCC_Lugano

Honored to learn from Dr. Henry Park’s novel approach integrating BgRT and SBRT within a single treatment plan for lung and kidney metastases at ASTRO 2025. Thank you for sharing your expertise and valuable experience. #ASTRO2025 #RadiationOncology #BgRT #SBRT #OncologyResearch

Honored to present my poster on clinically node-positive prostate cancer at #ASTRO2025. Grateful to my PI, Dr. Choi, for the guidance and the valuable discussions. #PosterPresentation #ProstateCancer #Oncology #Research

Thrilled to start the IDSO Fellowship FY26 at MD Anderson! Grateful for the chance to learn and deepen skills in digital twin for cancer care. Looking forward to turning data into insights that can truly help patients. #MDAnderson #IDSOFellowshipFY26 #DigitalTwin #RadOnc

.@EurUrolOncol Phase 2 RCT (IP2-ATLANTA, n=81) Cytoreductive surgery/radiotherapy/ablation for de novo mHSPC showed feasibility (75% recruitment) and safety (11% pathologic CR, 7-18% grade ≥3 AEs). PMID:40517058 pubmed.ncbi.nlm.nih.gov/40517058/